Kerri Bally, MD
Critical Care Medicine · Gadsden, ALNPI 1245606805
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 122 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by GSK at 41.8% of the total. 2025 is the largest year on record at $974, 5.2 times the $186 reported in 2022.
Across 122 payments — averaging $19.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$1K
- AstraZeneca$384
- Sanofi$254
- Amgen$181
- Insmed, Inc.$126
- Regeneron Healthcare Solutions, Inc.$114
- plus $349 from 11 others
What the payments were for
- Food & beverage$2,40499%
- Education$161%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 61 | $1,011 |
| AstraZeneca | 17 | $384 |
| Sanofi | 9 | $254 |
| Amgen | 9 | $181 |
| Insmed, Inc. | 5 | $126 |
| Regeneron Healthcare Solutions, Inc. | 4 | $114 |
| Philips North America LLC | 4 | $64 |
| Mylan Specialty L.p. | 3 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $35 |
| Vifor Pharma, Inc. | 1 | $34 |
| Harmony Biosciences LLC | 1 | $31 |
| Verona Pharma, Inc. | 1 | $26 |
| Viatris Specialty LLC | 1 | $26 |
| Boehringer Ingelheim | 1 | $22 |
| United Therapeutics Corporation | 1 | $21 |
| Electromed, Inc. | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
How this compares
$2,420 in reported general payments places this provider in the 75th percentile of 73 critical care medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 389 | $277,402 |
| OfevNintedanib Esylate | 21 | $275,457 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 127 | $93,602 |
| Spiriva RespimatTiotropium Bromide | 44 | $22,045 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $15,276 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 385 | $11,187 |
| DuleraMometasone/Formoterol | 33 | $10,033 |
| Incruse ElliptaUmeclidinium Bromide | 22 | $8,129 |
| SymbicortBudesonide/Formoterol Fumarate | 33 | $7,971 |
| Varenicline Tartrate | 14 | $4,672 |
| Prednisone | 83 | $3,804 |
| BreynaBudesonide/Formoterol Fumarate | 20 | $3,530 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 17 | $3,417 |
| Montelukast Sodium | 165 | $1,744 |
| Ventolin HfaAlbuterol Sulfate | 27 | $1,504 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $1,011 | $300,807445 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $22 | $297,50265 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $384 | $101,572160 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 73 critical care medicine providers in Alabama.
Other critical care medicine in Gadsden
- Faris Al-FarisGadsden$593
- James WellsBirmingham$223K
- Mark DransfieldBirmingham$160K
- George SolomonBirmingham$113K
- Tracy LuckhardtBirmingham$28K
- Keith WilleBirmingham$9K
- Victor ThannickalBirmingham$8K
- Kristy BarrentineDaphne$6K
- Vipul ShahBirmingham$6K
- Samuel McElweeBirmingham$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.